The federal agency said healthcare professionals should restrict the use of fluoroquinolone antibiotics for patients with sinusitis, bronchitis and uncomplicated urinary tract infections unless no other treatment options are available.
After the FDA reviewed the antibiotic, it found it is associated with disabling and possibly permanent side effects involving tendons, muscles, joints, nerves and the central nervous system.
In addition to the safety announcement, the FDA is now also requiring labeling changes for fluoroquinolones to reflect new information on the possible side effects.
More articles on antibiotics:
FDA issues new reporting requirements for sales of antibiotics given to food-producing animals
Researchers look to mushroom isolates to develop antibiotics
How 7 hospitals approach antibiotic stewardship
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
